Recent Updates
Recently added Catalysts

Stevanato Group S.p.A.

STVNFDA catalysts, PDUFA dates & pipeline intelligence
$15.8
▲ +1.44 · +10.03%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full STVN financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $12.0552W HIGH $24.01
Volume
1.46 M
Value Traded
22.14 M
Short % Float
1.81%
Days to Cover
2.1
+15.08%Week
-16.93%1 Month
-25.68%3 Month
-11.19%6 Month
+8.17%5 Year
+8.17%All Time

Cash Data

Unlock STVN cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
4.78 B
EPS (TTM)
0.60
P/E Ratio
26.30
Ent. Value
5.30 B
Total Shares
302.84 M
Float Shares
48.94 M
Insiders
82.08%
Institutions
16.67%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every STVN catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

STVN Catalyst Timeline

Dated clinical, regulatory and corporate events for Stevanato Group S.p.A.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Stevanato Group S.p.A.

5Total events
0Upcoming
2Tier-1 (high impact)
2026 to 2026Coverage

Event history 3

▲Quarterly UpdateCorporate
Stevanato Group reports Q2 2026 financial results
●Timing GuidancePresentation
Conference call and webcast to discuss Q2 2026 financial results
●AcquiredCorporate
Completed sale of California-based subsidiary Balda C. Brewer, Inc.
Unlock the full STVN catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How STVN actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all STVN historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

No drug pipeline

Stevanato Group S.p.A. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.

Clinical Trial Results

Readouts, endpoints and source filings for every STVN program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every STVN trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock STVN insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
FEDERICI WILLIAM JDirectorBuy 20,000 46,991 held$13.72 11/09/2026
Unlock the full STVN insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
TRI LOCUM PARTNERS LP 2 % (11.1 %) 8.57 M 332.91 K 89.5% ( 157.23 K)
Unlock every fund holding STVN
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in STVN
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see STVN ownership
Insider and institutional ownership, quarter by quarter.

STVN Short Interest

Shares sold short, counted twice a month.

1.81%
Short % of Float
of tradable shares sold short
886.3K
Shares Sold Short
-8.2% vs prior count
2.1 Moderate
Days to Cover
trading days of normal volume to buy every short share back
413.4K
Avg Daily Volume
the average used for days to cover
Unlock STVN short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock STVN option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live STVN option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock STVN options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How STVN ranks across every disease it competes in

Competitive Position is a premium feature
See how STVN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

STVN News

STVN
Nov 16, 2026
STVNConferences/Events
▲ +10%today

Stevanato Group to Participate in Upcoming Investor Conferences

Stevanato Group announced participation in the Jefferies Global Healthcare Conference in London from November 16 to 19, 2026. The company will also attend two other upcoming investor events. This engagement allows management to discuss business updates with the investment community.

Read more →
STVN
Nov 3, 2026
STVNGeneral
▼ -28.6%on this news

Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026

Stevanato Group reported an 8% revenue increase to €326.1 million for Q3 2026, driven by growth in its Biopharmaceutical and Diagnostic Solutions Segment. The company maintained its fiscal year guidance, expecting revenue between €1.260 billion and €1.280 billion. However, it noted a decline in the Engineering Segment and anticipated lower GLP-1 revenues affecting future growth.

Read more →
STVN
Oct 27, 2026
STVNGeneral

Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System Selection

Stevanato Group and Aptar Pharma have announced a collaboration to enhance the evaluation of pre-filled syringe systems. This partnership will provide critical system-level data to help pharmaceutical companies make informed packaging decisions for sensitive biologics. The collaboration focuses on improving the performance of high-value syringe systems and elastomer components, addressing challenges in drug development.

Read more →
STVN
Oct 20, 2026
STVNConferences/Events

Stevanato Group to Report Third Quarter 2026 Financial Results on November 3, 2026

Stevanato Group S.p.A. will announce its financial results for the third quarter of 2026 on November 3, 2026. A conference call and webcast will follow at 8:30 a.m. (EDT) to discuss these results. Participants can pre-register for easier access to the call.

Read more →
STVN
Oct 1, 2026
STVNGeneral

Ensera launches alliance network with SHL Medical, Stevanato Group, Ypsomed, Argonaut and American Injectables

Ensera has launched the Ensera Alliance Network, which includes SHL Medical, Stevanato Group, Ypsomed, Argonaut Manufacturing Services, and American Injectables. This network aims to simplify the commercialization of drug-device combination products by improving coordination among suppliers. The initiative seeks to reduce risks and accelerate the transition to commercial supply for pharmaceutical companies.

Read more →
STVN
Sep 8, 2026
STVNConferences/Events

Stevanato Group to Participate in Two Upcoming Investor Conferences

Stevanato Group S.p.A. (NYSE: STVN) has announced its participation in two significant investor conferences. The first will be held on September 15 at the Morgan Stanley Annual Global Healthcare Conference in New York, followed by the BofA Global Healthcare Conference on September 22. These events aim to strengthen investor relations and showcase the company's offerings.

Read more →
STVN
Aug 4, 2026
STVNGeneral

Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026

Stevanato Group S.p.A. reported an 8% revenue growth for the second quarter of fiscal 2026, reaching €302.0 million. A significant portion of this revenue, 45%, came from high-value solutions. The company also noted an increase in its gross profit margin, indicating strong financial performance compared to the previous year.

Read more →
STVN
Jul 30, 2026
STVNFDA Updates

Liraglutide Combination Products Incorporating Stevanato Group's Alina® Pen Injector Received Marketing Authorizations in Multiple European Countries

Stevanato Group S.p.A. announced that its liraglutide-based combination products, utilizing the Alina® pen injector, have received marketing authorizations across several European countries. This development signifies a notable expansion for the company in the European pharmaceutical market. The authorizations pertain to finished combination products held by respective marketing entities.

Read more →
STVN
Jul 21, 2026
STVNGeneral

Stevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026

Stevanato Group S.p.A. will release its financial results for Q2 2026 on August 4, 2026. The announcement includes details about a conference call and webcast scheduled for the same day at 8:30 a.m. (EDT). This event will provide insights into the company's performance and future outlook.

Read more →
STVN
Jun 8, 2026
STVNGeneral

Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management

Stevanato Group has launched Deora™, a pen injector designed for subcutaneous delivery. This device targets diabetes and weight management, aiming to enhance patient experience. The introduction of Deora™ reflects the company's commitment to innovative healthcare solutions.

Read more →
STVN
Jun 3, 2026
STVNGeneral

Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders’ Meeting

Stevanato Group held an ordinary and extraordinary shareholders' meeting. The details of the results or decisions made during the meeting were not disclosed in the article. The announcement indicates ongoing corporate governance activities.

Read more →
STVN
May 26, 2026
STVNGeneral

Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders' Meeting All Resolutions Proposed to Shareholders Passed Piombino Dese, Italy, June 3rd, 2026. Stevanato Group S.p.A. (NYSE: STVN

Stevanato Group S.p.A. held its Ordinary and Extraordinary Shareholders' Meeting on June 3rd, 2026, in which all proposed resolutions were approved. Shareholders granted new authorizations for share purchases and amendments to the Company's By-laws to facilitate corporate rights and governance. A new Board of Directors was appointed, alongside the approval of PricewaterhouseCoopers S.p.A. as the external auditor for financial statements up to the end of 2028. Additionally, a dividend of EUR 0.054 was approved for each share.

Read more →
STVN
May 11, 2026
STVNGeneral

Published on

Stevanato Group S.p.A. will hold its Ordinary and Extraordinary General Meeting of Shareholders on May 26, 2026, via teleconference. Shareholders holding ordinary shares on the Record Date have rights to attend and vote, while beneficial owners must follow specific procedures to record their votes. The meeting will cover the appointment of members to the Board of Directors among other agenda items, emphasizing adherence to the Company's Bylaws and relevant civil codes.

Read more →
STVN
May 7, 2026
STVNGeneral
▼ -5.1%on this newsshared move

Q1 2026 Financial Results Safe Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that ref

Stevanato Group's Q1 2026 financial results presentation includes forward-looking statements that caution about various risks and uncertainties affecting the company's future performance. Key concerns include potential interruptions in operations, the complexities of product offerings, intense competition for skilled employees, and geopolitical factors that could negatively impact business. The statements emphasize that actual results may differ materially from the predictions made due to these various risks.

Read more →
STVN
May 7, 2026
STVNGeneral
▼ -5.1%on this newsshared move

Stevanato Group Delivers 7% Revenue Growth (10% at Constant Currency) for the First Quarter of Fiscal 2026 - The Company Maintains Fiscal 2026 Guidance -

Stevanato Group S.p.A. reported a 7% increase in revenue for the first quarter of 2026, reaching €273.6 million, supported by growth in its Biopharmaceutical and Diagnostic Solutions segment. The company's adjusted EBITDA margin improved to 23.9%, reflecting operational efficiencies. Despite revenue declines in the Engineering Segment and challenges with depreciation, Stevanato maintains its fiscal guidance for the year, anticipating total revenue between €1.26 billion and €1.29 billion. The CEO expressed confidence in the company's strategic investments and focus on high-value solutions.

Read more →
STVN
May 7, 2026
STVNGeneral
▼ -5.1%on this newsshared move

Stevanato Group Delivers 7% Revenue Growth (10% at Constant Currency) for the First Quarter of Fiscal 2026

Stevanato Group reported a 7% revenue growth for Q1 2026, reaching €273.6 million, with high-value solutions accounting for 47% of total revenue. The Biopharmaceutical and Diagnostic Solutions segment drove this growth with a 13% increase. Despite a decline in the Engineering Segment, the company maintained its fiscal guidance for the year, expecting revenue between €1.26 billion and €1.29 billion.

Read more →
STVN
May 4, 2026
STVNConferences/Events

Stevanato Group to Participate in Three Upcoming Investor Conferences

Stevanato Group is set to participate in three upcoming investor conferences. The details regarding the specific conferences and their dates were not provided in the article. This participation indicates the company's ongoing engagement with investors and stakeholders.

Read more →
STVN
Apr 23, 2026
STVNConferences/Events

Stevanato Group to Report First Quarter 2026 Financial Results on May 7, 2026

Stevanato Group S.p.A. will release its financial results for Q1 2026 on May 7, 2026, at 6:30 a.m. EDT. A conference call and webcast will follow at 8:30 a.m. EDT, where management will discuss the results. Participants can pre-register for immediate access and will have the opportunity to ask questions during the call.

Read more →
STVN
Mar 13, 2026
STVNConferences/Events

Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum

Stevanato Group S.p.A. will participate in the KeyBanc Capital Markets Virtual Healthcare Forum on March 17-18, 2026. The company is set to present on March 17 from 9:45 to 10:20 a.m. ET, with a live webcast available on its website. A replay of the event will be accessible for 90 days post-forum.

Read more →
STVN
Mar 4, 2026
STVNGeneral
▲ +18.8%on this news

Stevanato Group Delivers 7% Revenue Growth (9% at Constant Currency) for Fiscal Year 2025, Including Record Revenue from High-Value Solutions and Expanded Margins

Stevanato Group reported a 7% revenue growth for fiscal year 2025, reaching €1.186 billion, with high-value solutions contributing significantly. The fourth quarter saw a 5% revenue increase, driven by strong performance in the Biopharmaceutical and Diagnostic Solutions Segment. The company anticipates continued growth in fiscal 2026, projecting revenue between €1.26 billion and €1.29 billion.

Read more →

About Stevanato Group S.p.A.

5,795 employees stevanatogroup.com
BIOPHARMAWATCH ELITE
Trade the next STVN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime